Merck KGaA (XSWX:MER) YoY EPS Growth: -14.31% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:MER Merck KGaA XSWX:MER
84 GF Score
Price CHF130.50
GF Value CHF135.81
! 10 Warning Signs
View Full Analysis

What is Merck KGaA YoY EPS Growth?

Merck KGaA XSWX:MER -1.92% 84 YoY EPS Growth is -14.31% as of Mar. 2026. GuruFocus rates XSWX:MER with a GF Score™ of 84/100 and a GF Value™ of CHF135.81. The stock has 10 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Merck KGaA's YoY EPS Growth for the quarter that ended in Mar. 2026 was -14.31%.

Merck KGaA's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was CHF1.38.

Merck KGaA YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Merck KGaA's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck KGaA YoY EPS Growth Chart

Merck KGaA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.13 3.20 -18.93 -2.53 -6.15

Merck KGaA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.47 4.45 10.58 -51.95 -14.31
XSWX:MER
84GF Score
Merck KGaA XSWX:MER
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck KGaA YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Merck KGaA's YoY EPS Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EPS Growth (A: Dec. 2025 )
=(Earnings per Share (Diluted) (A: Dec. 2025 )-Earnings per Share (Diluted) (A: Dec. 2024 ))/ | Earnings per Share (Diluted) (A: Dec. 2024 ) |
=(5.599-5.966)/ | 5.966 |
=-6.15 %

Merck KGaA's YoY EPS Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EPS Growth (Q: Mar. 2026 )
=(Earnings per Share (Diluted) (Q: Mar. 2026 )-Earnings per Share (Diluted) (Q: Mar. 2025 )) / | Earnings per Share (Diluted) (Q: Mar. 2025 )) |
=(1.383-1.614)/ | 1.614 |
=-14.31 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of -14.31% mean?
Merck KGaA (XSWX:MER) has a YoY EPS Growth of -14.31% as of Mar. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Merck KGaA and its competitors.
Is Merck KGaA's YoY EPS Growth too high?
Merck KGaA's current YoY EPS Growth is -14.31%. Overall, Merck KGaA has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does Merck KGaA's YoY EPS Growth compare to ZTS and UTHR?
Merck KGaA's YoY EPS Growth of -14.31% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Drug Manufacturers company?
A good YoY EPS Growth depends on the Drug Manufacturers industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Merck KGaA and its competitors. Merck KGaA's current YoY EPS Growth is -14.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck KGaA stock overvalued right now?
Merck KGaA (XSWX:MER) has a current YoY EPS Growth of -14.31%. The stock's GF Value™ is CHF135.81, compared to a current price of CHF130.50 — trading 3.9% below its estimated fair value. The current YoY EPS Growth is -14.31%. Merck KGaA's overall GF Score™ is 84/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Merck KGaA (XSWX:MER), the current YoY EPS Growth is -14.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck KGaA (XSWX:MER) Overvalued in 2026?

Based on GuruFocus' analysis, Merck KGaA stock appears to be undervalued. The current stock price of CHF130.50 is trading 3.9% below its estimated GF Value™ of CHF135.81.

Key valuation signals for XSWX:MER:

  • YoY EPS Growth: -14.31%
  • GF Value™: CHF135.81 vs. price of CHF130.50 (3.9% below fair value)
  • GF Score™: 84/100 with 10 warning signs

No single metric tells the full story. See the XSWX:MER stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Merck KGaA Business Description

Address Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
84GF Score

Get the complete analysis for XSWX:MER

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF130.50
Price
CHF135.81
GF Value